**Question:** Drug contraindicated in bilateral renal artery stenosis

**Core Concept:**
A bilateral renal artery stenosis refers to the narrowing or blockage of both renal arteries, which supply blood to the kidneys. This condition can lead to reduced renal perfusion and impaired kidney function. The correct answer focuses on drugs that may exacerbate this condition or cause harm to the kidneys due to reduced perfusion.

**Why the Correct Answer is Right:**
The correct answer should be a drug that could worsen the renal ischemia in bilateral renal artery stenosis, leading to further kidney injury. Drugs that increase intrarenal vascular resistance, such as vasoconstrictors, or those causing direct nephrotoxicity are generally contraindicated in this setting.

**Why Each Wrong Option is Incorrect:**

A. **Option A (Calcium channel blockers):** These medications work by relaxing the smooth muscle in the renal arteries, thereby reducing intrarenal vascular resistance and potentially improving renal perfusion, which would be beneficial in bilateral renal artery stenosis. Therefore, this option is incorrect.

B. **Option B (Angiotensin converting enzyme inhibitors):** Similarly to calcium channel blockers, ACE inhibitors reduce intrarenal vascular resistance and improve renal perfusion. This option is also incorrect for the same reason as option A.

C. **Option C (Antiplatelet agents):** While antiplatelet agents such as aspirin are essential in preventing cardiovascular events, their use in bilateral renal artery stenosis could lead to further reduction in renal blood flow and exacerbate renal ischemia.

D. **Option D (Antihypertensive drugs):** Similar to the above options, antihypertensive drugs generally improve renal perfusion by reducing systemic blood pressure and thus intrarenal vascular resistance. In bilateral renal artery stenosis, these medications could worsen renal ischemia.

**Clinical Pearl:**
In cases of bilateral renal artery stenosis, it is essential to avoid medications that could exacerbate renal ischemia or induce nephrotoxicity. Instead, clinicians should focus on medications that protect the kidneys from further injury and preserve renal function. These might include angiotensin II receptor blockers (ARBs), which have a different mechanism of action compared to ACE inhibitors and calcium channel blockers, and are generally considered safer in this context.